SCHEMBL935406

SCHEMBL935406

O=C1CC(C(=O)O)CC(=O)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 2/20 0.46
CYP2C19 P33261 2/20 0.42
ALDH1A1 P00352 2/20 0.41
APLNR P35414 1/20 0.39
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
TSHR P16473 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
GABRA4 P48169 1/20 0.39
GABRE P78334 1/20 0.39
PMP22 Q01453 1/20 0.39
GABRA6 Q16445 1/20 0.39
GABRG1 Q8N1C3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12435982 0.77 CRBN (0.50) CRBNCYP2C19ALDH1A1ITGB3ITGB1
SCHEMBL23728065 0.77 CRBN (0.44) CRBNALDH1A1ITGB3ITGB1ITGAV
SCHEMBL935426 0.77 KMT2A (0.50) CRBNALDH1A1ITGB3ITGB1ITGAV
SCHEMBL7944860 0.75 CREBBP (0.58) ALDH1A1TSHRMAPTGAA
SCHEMBL437804 0.75
SCHEMBL14749839 0.75
SCHEMBL761123 0.75
SCHEMBL301495 0.75
Ammonia Solution, Strong SCHEMBL2888472 0.73 GABRP (0.42) CYP2C19GABRPGABRDGABRA1TSHR
SCHEMBL11299879 0.73 GABRP (0.42) CYP2C19GABRPGABRDGABRA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122069877-A Perovskite solar cell 中茂绿能科技(西安)有限公司 2026-05-19 CN claimed
CN-122069877-A Perovskite solar cell 中茂绿能科技(西安)有限公司 2026-05-19 CN disclosed
WO-2025051102-A1 DEUTERATED TETRACYCLIC DERIVATIVE AND USE THEREOF 浙江我武翼方药业有限公司 2025-03-13 WO disclosed
CN-119591611-A Deuterated tetracyclic derivative and application thereof 浙江我武翼方药业有限公司 2025-03-11 CN disclosed
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 CN disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
CN-116462661-A Deuterated 3- (pyridin-4-yl) propionic acid compound, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-07-21 CN disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 US disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 US disclosed
US-20230014907-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-01-19 US disclosed
WO-2007089031-A1 PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-09 WO disclosed
US-20070149570-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-28 US disclosed
EP-1790636-A1 PIPERIDINE DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-05-30 EP disclosed
WO-2007015588-A1 PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-08 WO disclosed
EP-1748984-A1 PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS Pfizer Products Inc. (US) 2007-02-07 EP disclosed
US-20060241145-A1 Piperidine derivative crystal, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-10-26 US disclosed
EP-1705176-A1 CARBOXAMIDE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-09-27 EP disclosed
US-20060142337-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-29 US disclosed
WO-2005110987-A1 PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-24 WO disclosed
US-20050256164-A1 NK1 and NK3 antagonists PFIZER INC 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149570-A1 Piperidine derivative and use thereof TACR1, OPRL1, TRPV1 CRBN 2910/4885CYP2C19 977/4885ALDH1A1 915/4885
US-20050256164-A1 NK1 and NK3 antagonists TAC3, TACR1, TACR2 CRBN 2697/4885CYP2C19 2594/4885ALDH1A1 3567/4885
US-20230014907-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, NPC1L1 CRBN 2852/4885CYP2C19 2337/4885ALDH1A1 1965/4885
US-20060241145-A1 Piperidine derivative crystal, process for producing the same, and use PKD2, PKD1, TACR1 CRBN 4609/4885CYP2C19 3029/4885ALDH1A1 1532/4885
US-20060142337-A1 Piperidine derivative and use thereof AR, AHR, ARNT CRBN 1757/4885CYP2C19 138/4885ALDH1A1 26/4885
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES AIFM2, FECH, GPX4 CRBN 2737/4885CYP2C19 3675/4885ALDH1A1 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.